Articles from this edition:
Latest articles
‘One Million’ study to monitor COVID-19 vaccine safety and effectiveness
A UK consortium has announced plans for a 'One Million' Post-Authorisation Study to monitor the safety and effectiveness of the COVID-19 vaccine in real-life...
Advent Life Sciences announces sale of KaNDy Therapeutics to Bayer AG
Advent Life Sciences, a leading European life sciences venture capital firm, has announced the sale of its portfolio company, KaNDy Therapeutics Ltd, to Bayer...
FDA approves accelerated review for first-ever potential disease modifying Alzheimer’s drug
The US drug regulator, FDA has announced that the first-ever potential disease modifying Alzheimer’s drug, aducanumab, has been accepted for a priority review process. Samantha...
Popular articles
New Normal, New Thinking: Life Post COVID-19
New thinking will be required to adapt to the new normal life post COVID-19. I hate to start this article on a negative note, but...
Advent Life Sciences announces sale of KaNDy Therapeutics to Bayer AG
Advent Life Sciences, a leading European life sciences venture capital firm, has announced the sale of its portfolio company, KaNDy Therapeutics Ltd, to Bayer...
COVID-19: Pharma on the frontline
Pharma stepped up to support the NHS, the country and the World during the COVID-19 pandemic. Pf brings you some examples of pharma on...
Study shows anti-parasitic drug ivermectin kills coronavirus within 48 hours
A collaborative study led by the Monash Biomedicine Discovery Institute (BDI) with the Peter Doherty Institute of Infection and Immunity (Doherty Institute), a joint...
FDA approves accelerated review for first-ever potential disease modifying Alzheimer’s drug
The US drug regulator, FDA has announced that the first-ever potential disease modifying Alzheimer’s drug, aducanumab, has been accepted for a priority review process. Samantha...